Kathleen Murray, MD
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (38.8%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by Ipsen Pharma SAS at 47.4% of the total. Reporting peaked in 2022 at $1,144 and has fallen 89.9% since, to $115 in 2025.
Across 8 payments — averaging $301.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ipsen Pharma SAS$1K
- Argenx US, Inc.$938
- Alnylam Pharmaceuticals Inc.$250
- Biogen$30
- AstraZeneca$28
- Natus Medical Incorporated$25
Across 6 payments — averaging $4086.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$25K
What the payments were for
- Consulting fees$93839%
- Travel & lodging$87436%
- Food & beverage$60325%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ipsen Pharma SAS | 2 | $1,144 |
| Argenx US, Inc. | 1 | $938 |
| Alnylam Pharmaceuticals Inc. | 2 | $250 |
| Biogen | 1 | $30 |
| AstraZeneca | 1 | $28 |
| Natus Medical Incorporated | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,415 in reported general payments places this provider in the 55th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 11 | $231,229 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 15 | $158,301 |
| Mycophenolate Mofetil | 33 | $4,092 |
| Riluzole | 35 | $3,468 |
| Pyridostigmine Bromide | 38 | $2,786 |
| Gabapentin | 97 | $2,467 |
| Duloxetine Hcl | 81 | $1,039 |
| Atropine Sulfate | 12 | $513 |
| Tizanidine Hcl | 13 | $341 |
| Baclofen | 21 | $332 |
| Pregabalin | 31 | $314 |
| Sodium Chloride0.9 % Sodium Chloride | 23 | $143 |
| Prednisone | 31 | $131 |
Paid to pharmacies, not to this prescriber.
Other neurology in Tampa
- Selim BenbadisTampa$2.1M
- Derrick RobertsonTampa$1.8M
- Robert HauserTampa$1.6M
- David RoseTampa$1.4M
- Mark CascioneTampa$1.2M
- Tuan VuTampa$1M
- Katherine StandleyTampa$735K
- Susan SteenTampa$341K
- Rossitza ChichkovaTampa$294K
- Brody HenkelTampa$262K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.